The holy grail of Parkinson’s research is a therapy that will slow or stop the disease, and this year we made great strides toward such a treatment.
“I feel like we’re in one of the peak periods in terms of innovation and the exciting science that has moved from the laboratory,” says MJFF CEO Todd Sherer, PhD, in our latest podcast.
He covers some of those therapies in human testing – approaches targeting the protein alpha-synuclein, a calcium channel blocker – in this podcast, and we’ll dig deeper into each in our October 15 webinar on the same topic.
Join us in our next Third Thursdays webinar to hear more about therapies to slow or stop the Parkinson’s process and how you can get involved in studies.
